Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

Assembly Bio Advances Herpes and HDV Programs, Reports Q1 2026 Financials

Assembly Biosciences reported its first quarter 2026 financial results and recent operational highlights. The company completed Phase 1b studies for ABI-5366 and ABI-1179, helicase-primase inhibitors for recurrent genital herpes, reinforcing confidence in their safety and efficacy. Additionally, chronic toxicology studies for ABI-6250, an oral small-molecule entry inhibitor for chronic hepatitis delta virus, were completed, with Phase 2 initiation anticipated in Q4 2026. As of March 31, 2026, Assembly Bio held $226.6 million in cash, cash equivalents, and marketable securities, projecting a cash runway into 2028. The company also expects to decide on a 40% U.S. cost-profit share opt-in for the herpesvirus program with Gilead by mid-2026.

• Advancement of Herpesvirus Program: Assembly Biosciences completed the follow-up period for all participants in the Phase 1b studies of ABI-5366 and ABI-1179, its helicase-primase inhibitors for recurrent genital herpes. This milestone reinforces the previously disclosed positive safety and efficacy findings, with interim Phase 1b data also presented at the 2026 ESCMID Congress.
• Progress in Hepatitis Delta Virus Program: The company successfully completed chronic toxicology studies for ABI-6250, an oral small-molecule entry inhibitor designed for chronic hepatitis delta virus. These studies provide crucial support for anticipated Phase 2 doses, and Assembly Bio expects to initiate a Phase 2 clinical study for ABI-6250 in the fourth quarter of 2026.
• Financial Stability and Strategic Collaboration: Assembly Bio reported a strong financial position with $226.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026, projecting its operations to be funded into 2028. The company is also preparing to make a key decision by mid-2026 regarding opting into a 40% U.S. cost-profit share for its helicase-primase inhibitor program with Gilead Sciences.

The Persistent Unmet Needs in Recurrent Genital Herpes

Recent literature identifies several key unmet needs in recurrent genital herpes management, highlighting both therapeutic gaps and specific patient populations requiring targeted interventions. These findings emphasize the need for improved treatment options beyond current antiviral therapies and better management strategies for high-risk groups.

• Patients with frequent recurrences (more than 4-6 times annually) remain a primary target population for enhanced suppressive therapy approaches, with treatment stratified by episode frequency (<10 vs ≥10 episodes per year)

• Immunocompromised patients represent a significant unmet need due to increased risk for herpesvirus infection and reactivation, requiring specialized management protocols

• Pregnant women constitute a critical population where genital herpes can have substantial clinical impact, necessitating safe and effective treatment options during pregnancy

• Women of reproductive age face potential fertility implications, though sparse literature exists investigating the association between genital HSV infection and female infertility

• Healthcare provider education gaps present a systemic unmet need, with only 22.9% of Israeli healthcare providers demonstrating full familiarity with local management guidelines and critical knowledge gaps in transmission risks

• Sexual partners of infected patients require comprehensive counseling on natural history, transmission risks, treatment options, and management strategies as an integral component of care

• Patients with acyclovir-resistant viral strains need alternative therapeutic options, highlighting the demand for novel antiviral mechanisms beyond current nucleoside analogues

Dual-Front Advancement: Reshaping Antiviral Treatment Paradigms

Assembly Biosciences is making notable strides in its antiviral pipeline, particularly with its programs targeting recurrent genital herpes and chronic hepatitis delta virus (HDV). The successful completion of Phase 1b studies for ABI-5366 and ABI-1179, novel helicase-primase inhibitors (HPIs) for herpes, signals a promising path forward. This class of drugs has shown compelling efficacy in preclinical and early clinical studies, often outperforming traditional nucleoside analogues like valacyclovir by significantly reducing viral shedding and lesion frequency. HPIs also hold potential for addressing nucleoside analogue-resistant strains and severe infections, which represent a critical unmet need given the high global prevalence of herpes simplex virus. However, the historical experience with other HPIs, such as pritelivir facing a clinical hold due to nonclinical toxicity, underscores the importance of rigorous safety monitoring as these candidates progress.

Simultaneously, the company is advancing ABI-6250, an oral small-molecule entry inhibitor for chronic HDV, with Phase 2 initiation anticipated in Q4 2026 following completed chronic toxicology studies. HDV is the most severe form of viral hepatitis, leading to accelerated cirrhosis and hepatocellular carcinoma. The landscape for HDV treatment has recently evolved with the conditional approval of bulevirtide, an injectable entry inhibitor, which has demonstrated excellent long-term efficacy and safety, even in patients with advanced compensated and some decompensated cirrhosis. ABI-6250, as an oral agent, could offer a significant convenience advantage, but it will need to demonstrate comparable or superior efficacy and safety to carve out a strong market position against an established competitor.

The company's robust financial position, with a cash runway extending into 2028, provides a solid foundation for these ambitious development efforts. A key strategic inflection point will be the mid-2026 decision regarding a 40% U.S. cost-profit share opt-in for the herpesvirus program with Gilead. This partnership could significantly de-risk and accelerate the commercialization pathway for the herpes candidates, while the HDV program continues its independent trajectory. The coming quarters will be crucial in determining the long-term impact of these novel antiviral strategies.